Nivestym

Nivestym (filgrastim-aafi) is a biosimilar form of filgrastim, a recombinant human granulocyte colony-stimulating factor used to reduce the risk of infection in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy. Chemotherapy often causes neutropenia, a condition marked by low neutrophil counts that increases susceptibility to serious infections. It helps stimulate neutrophil production, shortening the duration of neutropenia and improving patient safety during cancer treatment.
Filgrastim-aafi works by binding to specific receptors on hematopoietic cells in the bone marrow, stimulating proliferation, differentiation, and activation of neutrophil precursors. This results in increased production and release of functional neutrophils into the bloodstream. By restoring neutrophil levels, Nivestym supports immune defense and allows patients to maintain planned chemotherapy dosing schedules without unnecessary delays.
Nivestym is administered by subcutaneous injection or intravenous infusion, with dosing individualized based on patient weight, chemotherapy regimen, and clinical response. It is typically given daily until neutrophil recovery is achieved. Clinical studies have demonstrated that it has comparable efficacy, safety, and immunogenicity to the reference product, filgrastim.
Common side effects include bone pain, headache, fatigue, nausea, and injection-site reactions, which are usually mild to moderate. Serious adverse events are uncommon. Overall, it provides a cost-effective, reliable option for preventing chemotherapy-induced neutropenia, supporting continuity of cancer treatment, reducing infection risk, and improving outcomes for patients undergoing intensive anticancer therapy. Its availability as a biosimilar increases treatment access, lowers healthcare costs, and supports broader use of evidence-based supportive care strategies in oncology practice worldwide for patients, providers, and healthcare systems globally today effectively.